Author + information
- S1936879816001941-25281bcbc88e46dfdf56a5cf1954fda1Perwaiz M. Meraj,
- S1936879816001941-6511b2d527ad1a5f5fe9bd2a12791a47Anmol Singh,
- S1936879816001941-80f20889dc252e01f47cc95f34f289b0Sheryl Kompancaril,
- S1936879816001941-eb5ec9e308be39fde54139c737ed64e8Parsa Tafreshi and
- S1936879816001941-b40dfc9884b533553c94076d33ee6079Liana Tatarian
Despite marked advances of revascularization, acute myocardial infarction (MI) remains a major cause of mortality. There is a greater than 50% mortality among patients presenting with acute myocardial infarction and cardiogenic shock (AMI-CS). We aim to determine if there are predictors to mortality in AMI-CS even when treated with Impella LVAD support.
Retrospective study of 52 patients treated with Impella 2.5 OR Impella CP was collected (Jan 2011 to Jan 2015). Baseline demographics were obtained. Unadjusted and adjusted analyses were performed to determine if there was an association with mortality by quantifying STS scores, ejection fraction (EF).
The use of Impella support in AMI-CS resulted in a mortality of 29%, significantly better than reported in previous studies. However, among patients who died from AMI-CS within 30 days of hospitalization, STS mortality over 10%, Morbidity and EF were all significantly worse (Table 1).
Impella LVAD support improves outcomes in AMI-CS patients undergoing PCI, with a significantly improved mortality than previously reported. Predictors of mortality in AMI-CS were found to be STS Mortality Score > 10% and EF <20%. Further data is needed to determine optimal treatment to improve mortality in AMI-CS.